Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Target |
Mechanism NK1 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date28 Mar 2022 |
Target |
Mechanism GHSR agonists |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. JP |
First Approval Date22 Jan 2021 |
Target |
Mechanism 5-HT3 receptor antagonists [+1] |
Active Org. |
Originator Org. |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date10 Oct 2014 |
Start Date09 Sep 2023 |
Sponsor / Collaborator |
Start Date07 Aug 2023 |
Sponsor / Collaborator |
Start Date01 Apr 2023 |
Sponsor / Collaborator Lahey Clinic [+2] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Netupitant/Palonosetron Hydrochloride ( 5-HT3 receptor x NK1 ) | Vomiting More | Approved |
Mechlorethamine Hydrochloride ( DNA ) | Mycosis Fungoides More | NDA/BLA |
Netupitant ( NK1 ) | Neoplasms More | Phase 3 Clinical |
Anamorelin Hydrochloride ( GHSR ) | Anorexia More | Phase 3 |
Fosnetupitant ( NK1 ) | Vomiting More | Phase 2 |